Skip to main content
. 2022 Jul 22;12:949513. doi: 10.3389/fonc.2022.949513

Figure 2.

Figure 2

Analysis of urine metabolomics of medulloblastoma, healthy controls, benign brain diseases, and malignant brain tumors. (A). PCA score plot of MB and controls in the discovery group. (B). ROC plot of the distinction between MB and controls in the validation Group (C). PCA score plot of MB and benign brain diseases in the discovery Group (D). ROC plot of the distinction between MB and benign brain diseases in the validation Group (E). PCA score plot of MB and other malignant tumors in the discovery group. (F). ROC plot of the distinction between MB and other malignant tumors in the validation group (G). Heatmap of 60 metabolites in MB, healthy controls, benign brain diseases and other malignant brain tumors.